Pharmacology Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pharmacology stocks.

Pharmacology Stocks Recent News

Date Stock Title
Nov 22 BLRX BioLineRx Q3 2024 Earnings Preview
Nov 22 SAGE Sage Therapeutics price target lowered to $4 from $7 at BofA
Nov 22 BLRX BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
Nov 21 SAGE Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
Nov 21 SAGE Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
Nov 21 BLRX BioLineRx inks licensing deal, share purchase agreement
Nov 21 BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Nov 20 SLGL SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Nov 20 SLGL Sol-Gel announces 180-day extension period for Nasdaq compliance
Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
Nov 20 BLRX BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Nov 20 SLGL Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Nov 20 SAGE Sage’s string of research failures continues
Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
Nov 19 SAGE CNS Drug Development: Same As It Ever Was
Nov 19 ARCT Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Pharmacology

Pharmacology is the branch of biology concerned with the study of drug action, where a drug can be broadly defined as any man-made, natural, or endogenous (from within the body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism (sometimes the word pharmacon is used as a term to encompass these endogenous and exogenous bioactive species). More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.
The field encompasses drug composition and properties, synthesis and drug design, molecular and cellular mechanisms, organ/systems mechanisms, signal transduction/cellular communication, molecular diagnostics, interactions, toxicology, chemical biology, therapy, and medical applications and antipathogenic capabilities. The two main areas of pharmacology are pharmacodynamics and pharmacokinetics. Pharmacodynamics studies the effects of a drug on biological systems, and Pharmacokinetics studies the effects of biological systems on a drug. In broad terms, pharmacodynamics discusses the chemicals with biological receptors, and pharmacokinetics discusses the absorption, distribution, metabolism, and excretion (ADME) of chemicals from the biological systems. Pharmacology is not synonymous with pharmacy and the two terms are frequently confused. Pharmacology, a biomedical science, deals with the research, discovery, and characterization of chemicals which show biological effects and the elucidation of cellular and organismal function in relation to these chemicals. In contrast, pharmacy, a health services profession, is concerned with application of the principles learned from pharmacology in its clinical settings; whether it be in a dispensing or clinical care role. In either field, the primary contrast between the two are their distinctions between direct-patient care, for pharmacy practice, and the science-oriented research field, driven by pharmacology.
The origins of clinical pharmacology date back to the Middle Ages in Avicenna's The Canon of Medicine, Peter of Spain's Commentary on Isaac, and John of St Amand's Commentary on the Antedotary of Nicholas. Clinical pharmacology owes much of its foundation to the work of William Withering. Pharmacology as a scientific discipline did not further advance until the mid-19th century amid the great biomedical resurgence of that period. Before the second half of the nineteenth century, the remarkable potency and specificity of the actions of drugs such as morphine, quinine and digitalis were explained vaguely and with reference to extraordinary chemical powers and affinities to certain organs or tissues. The first pharmacology department was set up by Rudolf Buchheim in 1847, in recognition of the need to understand how therapeutic drugs and poisons produced their effects.Early pharmacologists focused on natural substances, mainly plant extracts. Pharmacology developed in the 19th century as a biomedical science that applied the principles of scientific experimentation to therapeutic contexts. Today pharmacologists use genetics, molecular biology, biochemistry, and other advanced tools to transform information about molecular mechanisms and targets into therapies directed against disease, defects or pathogens, and create methods for preventative care, diagnostics, and ultimately personalized medicine.

Browse All Tags